Clinical Trials

Title   [286271-13] AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Description   The purpose of Part I of this study is to collect information on the leukemia and the effects of treatment. This will be given over 4 weeks. You already signed a consent form for the ALL Classification Study AALL08B1. For that reason, your doctor will know the risk group of the B-ALL by the end of Induction. We would like to begin treatment with chemotherapy (anti-cancer drugs) as soon as possible. The chemotherapy given during Induction is the current recommended treatment for Standard Risk (SR) B-ALL.
IRB Number   11-112
Treatment   Pediatric Oncology - Acute Lymphoblastic Leukemia
Status   Active
Principal Name   Felicia Wilson, M.D.
Contact Name   Andretta McCovey

Email Newsletters

Connect With Us